Sign in or create an account to add this stock to your watchlist.
About Proteonomix (OTCMKTS:PROT)
Proteonomix, Inc., a biotechnology company, focuses on developing therapeutics based upon the use of human cells and their derivatives. The company's products include Proteoderm, an anti-aging skin cream based on a proprietary and patented matrix of proteins that reduce wrinkles; UMK-121, a treatment for liver disease using a combination of two or three approved drugs to mobilize particular bone marrow stem cells; and StromaCel, a treatment for cardiac patients within two weeks of a myocardial infarction using stem cells derived from donor bone marrow and administered through IV solution to repair heart tissue. Its products also comprise NC-138, a proprietary matrix of proteins, which act on the skin to enhance activities that reduce wrinkles. The company was formerly known as National Stem Cell Holding, Inc. and changed its name to Proteonomix, Inc. in August 2008. Proteonomix, Inc. was incorporated in 1995 and is based in Hawthorne, New Jersey.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:PROT
CUSIPN/A
Phone+1-973-5446116
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity3,244.33%
Return on Assets90.15%
Miscellaneous
EmployeesN/A
Outstanding Shares7,910,000
Proteonomix (OTCMKTS:PROT) Frequently Asked Questions
What is Proteonomix's stock symbol?
Proteonomix trades on the OTCMKTS under the ticker symbol "PROT."
Who are some of Proteonomix's key competitors?
Who are Proteonomix's key executives?
Proteonomix's management team includes the folowing people:
- Mr. Michael Cohen, Founder, Chairman, CEO, Pres & COO (Age 51)
- Mr. Steven Byle J.D., Chief Technology Officer and Director (Age 50)
- Mr. Jason B. Isaacs, Sec. (Age 46)
- Ms. Jaci Mandil, Chief Exec. Officer of Proteoderm
Has Proteonomix been receiving favorable news coverage?
Media coverage about PROT stock has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Proteonomix earned a media sentiment score of 0.06 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 47.11 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
How do I buy shares of Proteonomix?
Shares of PROT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Proteonomix's stock price today?
One share of PROT stock can currently be purchased for approximately $0.0250.
How big of a company is Proteonomix?
Proteonomix has a market capitalization of $79,110.00.
How can I contact Proteonomix?
Proteonomix's mailing address is 187 Mill Ln, MOUNTAINSIDE, NJ 07092-2918, United States. The biotechnology company can be reached via phone at +1-973-5446116.
MarketBeat Community Rating for Proteonomix (PROT)
MarketBeat's community ratings are surveys of what our community members think about Proteonomix and other stocks. Vote "Outperform" if you believe PROT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PROT will underperform the S&P 500 over the long term. You may vote once every thirty days.
Proteonomix (OTCMKTS:PROT) Analyst Ratings History
| Date | Brokerage | Action | Rating | Price Target | Details |
|---|
(Data available from 5/21/2016 forward)
Proteonomix (OTCMKTS:PROT) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Proteonomix (OTCMKTS PROT) Insider Trading and Institutional Ownership History
Proteonomix (OTCMKTS PROT) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
Proteonomix (OTCMKTS PROT) News Headlines
| Source: |
|
No headlines for this company have been tracked by MarketBeat.com
Proteonomix (OTCMKTS:PROT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Proteonomix (OTCMKTS:PROT) Income Statement, Balance Sheet and Cash Flow Statement
Proteonomix (OTCMKTS PROT) Stock Chart for Monday, May, 21, 2018
Loading chart…
